Literature DB >> 18004886

Interactions of substrates at the surface of P450s can greatly enhance substrate potency.

Amita Hegde1, Donovan C Haines, Muralidhar Bondlela, Baozhi Chen, Nathaniel Schaffer, Diana R Tomchick, Mischa Machius, Hien Nguyen, Puneet K Chowdhary, Larissa Stewart, Claudia Lopez, Julian A Peterson.   

Abstract

Cytochrome P450s are a superfamily of heme containing enzymes that use molecular oxygen and electrons from reduced nicotinamide cofactors to monooxygenate organic substrates. The fatty acid hydroxylase P450BM-3 has been particularly widely studied due to its stability, high activity, similarity to mammalian P450s, and presence of a cytochrome P450 reductase domain that allows the enzyme to directly receive electrons from NADPH without a requirement for additional redox proteins. We previously characterized the substrate N-palmitoylglycine, which found extensive use in studies of P450BM-3 due to its high affinity, high turnover number, and increased solubility as compared to fatty acid substrates. Here, we report that even higher affinity substrates can be designed by acylation of other amino acids, resulting in P450BM-3 substrates with dissociation constants below 100 nM. N-Palmitoyl-l-leucine and N-palmitoyl-l-methionine were found to have the highest affinity, with dissociation constants of less than 8 nM and turnover numbers similar to palmitic acid and N-palmitoylglycine. The interactions of the amino acid side chains with a hydrophobic pocket near R47, as revealed by our crystal structure determination of N-palmitoyl-l-methionine bound to the heme domain of P450BM-3, appears to be responsible for increasing the affinity of substrates. The side chain of R47, previously shown to be important in interactions with negatively charged substrates, does not interact strongly with N-palmitoyl-l-methionine and is found positioned at the enzyme-solvent interface. These are the tightest binding substrates for P450BM-3 reported to date, and the affinity likely approaches the maximum attainable affinity for the binding of substrates of this size to P450BM-3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004886     DOI: 10.1021/bi701667m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

Review 1.  Conformational plasticity and structure/function relationships in cytochromes P450.

Authors:  Thomas C Pochapsky; Sophia Kazanis; Marina Dang
Journal:  Antioxid Redox Signal       Date:  2010-10       Impact factor: 8.401

2.  Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.

Authors:  Matthew L Danielson; Prashant V Desai; Michael A Mohutsky; Steven A Wrighton; Markus A Lill
Journal:  Eur J Med Chem       Date:  2011-06-23       Impact factor: 6.514

3.  Structural evidence: a single charged residue affects substrate binding in cytochrome P450 BM-3.

Authors:  Jaclyn Catalano; Kianoush Sadre-Bazzaz; Gabriele A Amodeo; Liang Tong; Ann McDermott
Journal:  Biochemistry       Date:  2013-09-16       Impact factor: 3.162

4.  A single active-site mutation of P450BM-3 dramatically enhances substrate binding and rate of product formation.

Authors:  Donovan C Haines; Amita Hegde; Baozhi Chen; Weiqiang Zhao; Muralidhar Bondlela; John M Humphreys; David A Mullin; Diana R Tomchick; Mischa Machius; Julian A Peterson
Journal:  Biochemistry       Date:  2011-09-06       Impact factor: 3.162

5.  Chain length-dependent cooperativity in fatty acid binding and oxidation by cytochrome P450BM3 (CYP102A1).

Authors:  Benjamin Rowlatt; Jake A Yorke; Anthony J Strong; Christopher J C Whitehouse; Stephen G Bell; Luet-Lok Wong
Journal:  Protein Cell       Date:  2011-09-09       Impact factor: 14.870

Review 6.  Rational and semi-rational engineering of cytochrome P450s for biotechnological applications.

Authors:  Lian-Hua Xu; Yi-Ling Du
Journal:  Synth Syst Biotechnol       Date:  2018-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.